GlassScriptPhysician profile
Virginia Singla
NPI 1952745929
$37,246.57
in general payments reported to CMS, 2019-2025
23 companies · $9,835 in 2025
The $9,835 reported for 2025 was more than what 80% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,096 · 2021: $2,264 · 2022: $4,670 · 2023: $11K · 2024: $7,386 · 2025: $9,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $11K · Consulting Fee: $5,688 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,529.10 |
| Travel and Lodging | $10,500.92 |
| Consulting Fee | $5,687.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12,815.27 | 2019-2025 | Farapulse, General - Therapies, Watchman Flx |
| Medtronic, INC. | $10,623.25 | 2021-2024 | Micra, Linq II, Selectsecure |
| Abbott Laboratories | $6,413.08 | 2019-2025 | Ensite Precision, Na, Tacticath Ablation Catheter, Sensor Enabled |
| Atricure, INC. | $2,148.20 | 2022-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,429.44 | 2022-2024 | Lifevest |
| Medical Device Business Services, INC. | $1,082.66 | 2024 | Carto 3 |
| Biosense Webster, INC. | $901.21 | 2023-2025 | Carto 3 |
| Cardiva Medical, INC. | $403.68 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade 6/7f Vcs |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.04 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $267.63 | 2022-2023 | Andexxa, Farxiga |
| Altathera Pharmaceuticals LLC | $184.99 | 2022-2025 | Sotalol Hydrochloride |
| Biotronik INC. | $163.94 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.40 | 2022 | |
| Irhythm Technologies, INC. | $127.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $91.51 | 2022-2024 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $50.42 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.36 | 2022-2023 | Camzyos |
| Teleflex LLC | $29.02 | 2025 | Vsi |
| Regeneron Healthcare Solutions, INC. | $27.94 | 2021 | |
| Heartflow, INC. | $16.81 | 2023 | Ffrct |
| Edwards Lifesciences Corporation | $13.22 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.19 | 2021 | |
| Pfizer INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.